BF-B vs CLX

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. Despite solid profitability metrics like a 29.44% operating margin and 20.67% ROE, the company faces declining revenue and earnings, with YoY revenue down 5.40% and earnings down 13.90%. The stock trades above the Graham Number of $18.30 at $27.57, supported by a 3.26% dividend yield and analyst target of $30.26, but weak recent earnings surprises and insider selling temper optimism.

The Clorox Company presents as a classic value trap, characterized by a stable Piotroski F-Score of 5/9 but severely undermined by a massive valuation gap, with a current price of $98.68 far exceeding its growth-based intrinsic value of $42.77. Financial health is concerning due to critical liquidity shortages, evidenced by a Quick Ratio of 0.38 and a Current Ratio of 0.74. Negative year-over-year revenue (-0.80%) and earnings (-16.20%) growth, combined with a 0/100 technical trend, indicate a strong bearish momentum. While the 5.03% dividend is attractive, the 80.52% payout ratio is increasingly risky given the declining earnings trajectory.